Florham Park, NJ (PRWEB) February 27, 2013
The United States (U.S.) Food and Drug Administration (FDA) has approved Osphena™ (ospemifene) tablets, Shionogi Inc.’s treatment for moderate to severe dyspareunia (painful intercourse), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. VVA is a chronic and progressive condition caused by decreased estrogen due to menopause in women.
Dyspareunia is one of the most common symptoms of VVA. Although approximately 32 million postmenopausal U.S. women experience the signs and symptoms of VVA, up to 70 percent of women who live with symptoms remain undiagnosed because many are not proactively addressing the condition with their healthcare professionals (HCPs).
Many women do not associate VVA with menopause and, because it is not a topic that is frequently discussed, they are unaware of how common this condition is among postmenopausal women. As a result, the symptoms of VVA, such as dyspareunia, are often unanticipated and may go untreated. However, while many symptoms of menopause, such as hot flashes or flushes, lessen or disappear with time, VVA usually persists and may even worsen without treatment.
“Women tend to accept dyspareunia as part of getting older, but they do not have to live in silence with the condition,” said David J. Portman, M.D., OB/GYN, Director of the Columbus Center for Women’s Health Research. “As a convenient once-daily oral medication, Osphena is an important treatment alternative for millions of women living with painful intercourse due to menopause.”
Prescription therapy is often required for symptomatic women. Osphena, as an estrogen agonist/antagonist with tissue selective effects, is the first and only oral treatment alternative to vaginal or oral estrogens fo
Copyright©2012 Vocus, Inc.
All rights reserved